On February 4, 2020 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), reported that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update at the BIO CEO & Investor Conference February 10-11, 2020 (Press release, Onconova, FEB 4, 2020, View Source [SID1234553807]). Dr. Fruchtman and members of management will be available for 1×1 meetings during the conference.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details
Date/Time: Tuesday, February 11th, 2:00-2:15 PM
Venue: Marriott Marquis 1535 Broadway New York, NY 10036
Wilder Room, 4th Floor
Presenter: Steven Fruchtman, CEO
A webcast of the presentation will be available one hour after the conclusion of the live event at http://www.veracast.com/webcasts/bio/ceoinvestor2020/78221591.cfm and can also be accessed via View Source on the Company’s website after the event.